Skip to main content

Denosumab News (Page 2)

FDA Approves Xgeva to Treat Giant Cell Tumor of the Bone

June 13, 2013 – The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and...

FDA Approves New Indications for Prolia (denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy

THOUSAND OAKS, Calif., September 19, 2011, 2011 /PRNewswire/ – Amgen today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia (denosumab) as a...

FDA Approves Amgen's Xgeva (denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors

THOUSAND OAKS, Calif., Nov. 18, 2010 /PRNewswire-FirstCall/ – Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Xgeva (denosumab), the first and only RANK...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Osteoporosis

Related drug support groups

Prolia

Denosumab patient information at Drugs.com